journal article·2014-08Open access

Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs

Wanyi Tai, Ran Mo, Yue Lu, Tianyue Jiang, Zhen Gu

Biomaterials· Volume 35· Issue 25

Abstract

A graft copolymer with pendant drug segments can fold into nanostructures in a protein folding-like manner. The graft copolymer is constructed by directly polymerizing γ-camptothecin-glutamate N-carboxyanhydride (Glu(CPT)-NCA) on multiple sites of poly(ethylene glycol) (PEG)-based main chain via the ring open polymerization (ROP). The "purely" conjugated anticancer agent camptothecin (CPT) is hydrophobic and serves as the principal driving force during the folding process. When exposed to water, the obtained copolymer, together with doxorubicin (Dox), another anticancer agent, can fold into monodispersed nanocarriers (with a diameter of around 50 nm) for dual-drug delivery. Equipped with a PEG shell, the nanocarriers displayed good stability and can be internalized by a variety of cancer cell lines via the lipid raft and clathrin-mediated endocytotic pathway without premature leakage, which showed a high synergetic activity of CPT and Dox toward various cancer cells. In vivo study validated that the nanocarriers exhibited strong accumulation in tumor sites and showed a prominent anticancer activity against the lung cancer xenograft mice model compared with free drugs.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (70)

Show source-provided references
1. Cancer multidrug resistance10.1038/5289 ↗
2. Cancer drug resistance: an evolving paradigm10.1038/nrc3599 ↗
3. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives10.2174/157015906776359568 ↗
4. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines10.1093/annonc/mdq200 ↗
5. Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop10.1158/1078-0432.CCR-12-2455 ↗
6. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial10.1200/JCO.1998.16.12.3720 ↗
7. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations10.1681/ASN.V1251059 ↗
8. High-dose cyclosporin with etoposide–toxicity and pharmacokinetic interaction in children with solid tumours10.1038/bjc.1998.383 ↗
9. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram10.1021/nn4010796 ↗
10. Synergistic drug combinations tend to improve therapeutically relevant selectivity10.1038/nbt.1549 ↗
11. Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF10.1021/mp9002514 ↗
12. Nanoparticle-assisted combination therapies for effective cancer treatment10.4155/tde.10.13 ↗
13. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance10.1016/j.jconrel.2009.09.004 ↗
14. Nanocarriers as an emerging platform for cancer therapy10.1038/nnano.2007.387 ↗
15. Nanotechnology in drug delivery and tissue engineering: from discovery to applications10.1021/nl102184c ↗
16. Cancer nanomedicine: from drug delivery to imaging10.1126/scitranslmed.3005872 ↗
17. ATP-triggered anticancer drug delivery10.1038/ncomms4364 ↗
18. Nanoparticles for combination drug therapy10.1021/nn405674m ↗
19. Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy10.1021/bc400166j ↗
20. A synergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles
21. Gel–liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy10.1002/adfm.201303222 ↗
22. Mechanism of action of DNA topoisomerase inhibitors10.1002/stem.5530130408 ↗
23. Camptothecin. Discovery to clinic10.1111/j.1749-6632.1996.tb26371.x ↗
24. Camptothecin and taxol: discovery to clinic–thirteenth Bruce F. Cain Memorial Award Lecture
25. Mechanisms of cellular resistance to camptothecins10.2174/092986706778773121 ↗
26. Mechanisms of resistance to camptothecins10.1111/j.1749-6632.2000.tb07024.x ↗
27. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors10.1093/jnci/81.22.1732 ↗
28. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines
29. Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines10.1016/0753-3322(90)90026-6 ↗
30. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants10.1054/bjoc.2001.2027 ↗
31. N-Trimethylsilyl amines for controlled ring-opening polymerization of amino acid N-carboxyanhydrides and facile end group functionalization of polypeptides10.1021/ja803304x ↗
32. One-pot synthesis of brush-like polymers via integrated ring-opening metathesis polymerization and polymerization of amino acid N-carboxyanhydrides10.1021/ja903425x ↗
33. Shell cross-linked polymer micelles: stabilized assemblies with great versatility and potential10.1016/S0927-7765(99)00060-0 ↗
34. Pi-pi stacking increases the stability and loading capacity of thermosensitive polymeric micelles for chemotherapeutic drugs10.1021/bm400234c ↗
35. Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance10.1016/S0168-3659(99)00133-9 ↗
36. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model10.1158/1078-0432.CCR-07-4456 ↗
37. The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles10.1016/j.biomaterials.2011.10.044 ↗
38. Structure/activity study of tris(2-aminoethyl)amine-derived translocases for phosphatidylcholine10.1021/jo016416s ↗
39. Optimizing saccharide-directed molecular delivery to biological receptors: design, synthesis, and biological evaluation of glycodendrimer-cyclodextrin conjugates10.1021/ja047864v ↗
40. A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer10.1007/s11095-013-1192-3 ↗
41. Cryoprotection-lyophilization and physical stabilization of rifampicin-loaded flower-like polymeric micelles10.1098/rsif.2011.0414 ↗
42. Toward the next-generation nanomedicines: design of multifunctional multiblock polyurethanes for effective cancer treatment10.1021/nn4002769 ↗
43. On the measurement of critical micelle concentrations of pure and technical-grade nonionic surfactants10.1007/s11743-000-0113-4 ↗
44. Effects of the pH dependence of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay
45. Development of a peptide-drug conjugate for prostate cancer therapy10.1021/mp200007b ↗
46. Expression profile and functional activity of peptide transporters in prostate cancer cells10.1021/mp300364k ↗
47. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles10.1016/j.biomaterials.2011.03.071 ↗
48. Graft and diblock copolymer multifunctional micelles for cancer chemotherapy and imaging10.1016/j.biomaterials.2009.11.059 ↗
49. The accumulation of dual pH and temperature responsive micelles in tumors10.1016/j.biomaterials.2012.02.059 ↗
50. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies10.1016/j.addr.2007.11.010 ↗
51. Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin10.1021/jm020022r ↗
52. Water-soluble poly-(L-glutamic acid)-gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo10.1016/S0168-3659(01)00323-6 ↗
53. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles10.1016/j.biomaterials.2010.01.065 ↗
54. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles10.2147/IJN.S36111 ↗
55. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels10.1002/ijc.11108 ↗
56. Chain Initiation efficiency in cobalt- and nickel-mediated polypeptide synthesis10.1021/ja994281q ↗
57. Photophysical studies of merocyanine 540 dye in aqueous micellar dispersions of different surfactants and in different solvents10.1016/j.saa.2006.06.030 ↗
58. The components of merocyanine-540 absorption spectra in aqueous, micellar and bilayer environments10.1111/j.1432-1033.1992.tb17145.x ↗
59. Effects of static quenching and light pulse intensity on the time-dependent fluorescence quenching kinetics10.1016/0301-0104(93)E0339-W ↗
60. Quantitative comparison of long-wavelength alexa fluor dyes to cy dyes: fluorescence of the dyes and their bioconjugates10.1177/002215540305101214 ↗
61. Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery10.1016/j.jconrel.2004.06.003 ↗
62. Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation10.1083/jcb.108.2.389 ↗
63. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation10.1083/jcb.123.5.1107 ↗
64. Selective caveolin-1-dependent endocytosis of glycosphingolipids10.1091/mbc.e02-12-0809 ↗
65. Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells10.1074/jbc.M708849200 ↗
66. A role for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages10.1083/jcb.135.5.1249 ↗
67. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.0.CO;2-Y ↗
68. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate10.2147/nano.2006.1.4.375 ↗
69. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models10.1158/1078-0432.CCR-05-1566 ↗
70. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet